CO5700753A2 - Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad - Google Patents

Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad

Info

Publication number
CO5700753A2
CO5700753A2 CO05105292A CO05105292A CO5700753A2 CO 5700753 A2 CO5700753 A2 CO 5700753A2 CO 05105292 A CO05105292 A CO 05105292A CO 05105292 A CO05105292 A CO 05105292A CO 5700753 A2 CO5700753 A2 CO 5700753A2
Authority
CO
Colombia
Prior art keywords
phenyl
paroxetine
methyl
piperazin
fluoro
Prior art date
Application number
CO05105292A
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Renzo Carletti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5700753A2 publication Critical patent/CO5700753A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Una combinación que comprende una dosis terapéuticamente no efectiva de paroxetina o sales fisiológicamente aceptables o solvatos de la misma y una dosis terapéuticamente no efectiva de [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metil-amida del ácido 2 -(S)-(4-fluoro-2-metil-fenil)piperazin-1-carboxílico o sales fisiológicamente aceptables o solvatos de la misma.2.- La combinación de conformidad con la reivindicación 1, caracterizada además porque la paroxetina está presente como su sal hemihidrato del clorhidrato y [1-(R)-(3,5-bis-trifluorometil-fenil)-etil]-metil-amida del ácido 2-(S)-(4-fluoro-2-metil-fenil)-piperazin-1-carboxílico está presente como la sal de metansulfonato.3.- La combinación de conformidad con las reivindicación 1 ó 2, que comprende paroxetina o sales fisiológicamente aceptables o solva!os de la misma en una cantidad 1 a 10 mg (medida como la base libre).4.- La combinación de conformidad con cualquiera de las reivindicaciones 1 a 3, que comprende paroxetina o sales fisiológicamente aceptables o solvatosde la misma en una cantidad de 3.5 a 7.5 mg (medida como la base libre).
CO05105292A 2003-04-17 2005-10-14 Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad CO5700753A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments

Publications (1)

Publication Number Publication Date
CO5700753A2 true CO5700753A2 (es) 2006-11-30

Family

ID=9956996

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05105292A CO5700753A2 (es) 2003-04-17 2005-10-14 Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad

Country Status (18)

Country Link
US (4) US20060217395A1 (es)
EP (4) EP1653956A1 (es)
JP (4) JP2006523652A (es)
KR (2) KR20060003875A (es)
CN (2) CN1809355A (es)
AU (2) AU2004229179A1 (es)
BR (2) BRPI0409379A (es)
CA (2) CA2522311A1 (es)
CO (1) CO5700753A2 (es)
GB (1) GB0308968D0 (es)
IS (2) IS8129A (es)
MA (2) MA27731A1 (es)
MX (2) MXPA05011063A (es)
NO (2) NO20055367L (es)
PL (2) PL377857A1 (es)
RU (2) RU2005135647A (es)
WO (4) WO2004091617A1 (es)
ZA (2) ZA200508067B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2287397A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
EP1237874B1 (en) * 1999-12-17 2006-02-22 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
EP1451153B1 (en) * 2001-11-13 2007-09-26 Schering Corporation Nk1 antagonists
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2004091617A1 (en) 2004-10-28
EP1615641A1 (en) 2006-01-18
RU2005135647A (ru) 2006-06-10
WO2004091615A1 (en) 2004-10-28
WO2004091616A1 (en) 2004-10-28
MXPA05011064A (es) 2006-04-18
CN1809359A (zh) 2006-07-26
AU2004229181A1 (en) 2004-10-28
RU2005135649A (ru) 2006-03-20
KR20060003875A (ko) 2006-01-11
US20060287325A1 (en) 2006-12-21
US20060241124A1 (en) 2006-10-26
JP2006523650A (ja) 2006-10-19
JP2006523649A (ja) 2006-10-19
NO20055367L (no) 2005-11-14
EP1615642A1 (en) 2006-01-18
CA2522311A1 (en) 2004-10-28
PL377858A1 (pl) 2006-02-20
CA2522313A1 (en) 2004-10-28
ZA200508068B (en) 2007-02-28
JP2006523652A (ja) 2006-10-19
MXPA05011063A (es) 2005-12-12
PL377857A1 (pl) 2006-02-20
BRPI0409377A (pt) 2006-04-25
MA27731A1 (fr) 2006-01-02
AU2004229179A1 (en) 2004-10-28
JP2006523651A (ja) 2006-10-19
IS8128A (is) 2005-11-15
ZA200508067B (en) 2007-02-28
GB0308968D0 (en) 2003-05-28
US20060241143A1 (en) 2006-10-26
CN1809355A (zh) 2006-07-26
BRPI0409379A (pt) 2006-04-25
EP1653956A1 (en) 2006-05-10
NO20055368L (no) 2005-11-14
WO2004091624A1 (en) 2004-10-28
KR20060003876A (ko) 2006-01-11
MA27730A1 (fr) 2006-01-02
EP1613325A1 (en) 2006-01-11
IS8129A (is) 2005-11-15
US20060217395A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
CO5700753A2 (es) Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad
CY1121338T1 (el) Χρηση αλατων του αναστολεα kinασης janus (r)-3-(4-(7h-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλο)-3-κυκλοπεντυλο- προπανονιτριλιο
AR030190A1 (es) Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo
RS54651B1 (en) JANUS KINAS INHIBITORS for the treatment of dry eye and other eye diseases
RS52743B (en) (2S, 3R) -N- (2 - ((3-PYRIDINYL) METHYL) -1-AZABICYCLO [2.2.2] OCT-3-IL) BENZOFURAN-2-CARBOXAMID, NEW FORMS OF SALTS AND PROCEDURES FOR THEIR USE
CY1110798T1 (el) Συνδυασμοι περιλαμβανοντες αντιμουσκαρινικους παραγοντες και αναστολεις pde4
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
NO20055496D0 (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
HRP20150196T1 (hr) Farmaceutske formulacije s ligandima receptora dopamina
DE50203788D1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
PA8622801A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CY1113894T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ροφλουμιλαστη και λεβοκετιριζινη
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
RS52941B (en) A COMBINATION OF ALFA 7 NICOTINE AGONISTS AND ANTIPSYCHOTICS
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
DOP2006000287A (es) Derivados de piperidina
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana

Legal Events

Date Code Title Description
FA Application withdrawn